Pancreastatin-dependent inflammatory signaling mediates obesity-induced insulin resistance

  1. Sushil K. Mahata1,2
  1. 1From the VA San Diego Healthcare System, San Diego, California, USA;
  2. 2Department of Medicine, University of California, San Diego, California, USA;
  3. 3Central Drug Research Institute, Lucknow, India
  1. Corresponding author: Sushil K. Mahata, E-mail: smahata{at}ucsd.edu

Abstract

Chromogranin A knockout (Chga-KO) mice exhibit enhanced insulin sensitivity despite obesity. Here we probed the role of the Chromogranin A-derived peptide pancreastatin (PST: CHGA273-301), by investigating the effect of diet-induced obesity (DIO) on insulin sensitivity of these mice. We found that on a high fat diet (HFD), Chga-KO mice (KO-DIO) remain more insulin sensitive than wild-type DIO (WT-DIO) mice. Concomitant with this phenotype is enhanced Akt and AMPK signaling in muscle and white adipose tissue (WAT) as well as increased FoxO1 phosphorylation and expression of mature Srebp-1c in liver and downregulation of the hepatic gluconeogenic genes, Pepck and G6pase. KO-DIO mice also exhibited downregulation of cytokines and pro-inflammatory genes and upregulation of anti-inflammatory genes in WAT, and peritoneal macrophages from KO mice displayed similarly reduced pro-inflammatory gene expression. The insulin-sensitive, anti-inflammatory phenotype of KO-DIO mice is masked by supplementing PST. Conversely, a PST variant peptide PSTv1 (PST-NΔ3: CHGA276-301), lacking PST activity, simulated the KO phenotype by sensitizing WT-DIO mice to insulin. In summary, the reduced inflammation due to PST deficiency prevented the development of insulin resistance in KO-DIO mice. Thus, obesity manifests insulin resistance only in the presence of PST, and in its absence obesity is dissociated from insulin resistance.

  • Received November 15, 2013.
  • Accepted July 12, 2014.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.